FDA Drug Safety Communication issued regarding an increased risk of hypomagnesemia (low magnesium levels) associated with PPI therapy.
2011 – FDA Drug Safety Communication issued
Announcement Date: March 2, 2011
FDA Drug Safety Communication issued regarding an increased risk of hypomagnesemia (low magnesium levels) associated with PPI therapy.